CliniOps, Inc., a leading provider of advanced Digital Clinical Trial solutions, today announced a strategic partnership with Indegene, to drive innovative digital transformation in clinical trial processes and achieve better patient outcomes. This collaboration marks a significant milestone in advancing the efficiency and effectiveness of clinical trial operations globally. With a client base that includes the world`s top 20 pharma companies, Indegene brings a strong track record of modernizing the industry with its deep domain expertise and life sciences-contextualized technology, spanning the entire product lifecycle from development to commercialization. Indegene`s aim to expand its footprint in the clinical trial domain complements CliniOps` cutting-edge technologies and capabilities in this space.Together, CliniOps and Indegene aim to deliver a joint vision of accelerating clinical trial conduct by redefining industry standards. As part of this collaboration, Indegene will provide its expertise in patient recruitment and data services, leveraging CliniOps` Unified Platform, that ensures high data quality, brings speed and streamlines data collection, from various data sources.Powered by Capital Market - Live News

Indegene announced that it is a winner in HealthTech at the Deloitte Technology Fast 50 India 2024 Awards, for the second consecutive year. Now in its 19th edition, the Deloitte Technology Fast 50 India programme celebrates and honours the fastest-growing technology-enabled businesses based on their average revenue growth over a three-year period.Powered by Capital Market - Live News

Indegene announced a new center in Hyderabad to strengthen its global delivery operations and better address growing business needs. As the pharma industry faces increasing pressure to innovate and adapt, this new center will play a key role in helping companies accelerate their transformation. This move aligns with Indegene`s purpose: to enable healthcare organizations to be future-ready by combining deep medical expertise with fit-for purpose technology. Powered by Capital Market - Live News

Net profit of Indegene rose 22.27% to Rs 91.70 crore in the quarter ended September 2024 as against Rs 75.00 crore during the previous quarter ended September 2023. Sales rose 8.04% to Rs 686.80 crore in the quarter ended September 2024 as against Rs 635.70 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales686.80635.70 8 OPM %18.3619.05 - PBDT143.50120.40 19 PBT124.10100.60 23 NP91.7075.00 22 Powered by Capital Market - Live News

Indegene will hold a meeting of the Board of Directors of the Company on 28 October 2024.Powered by Capital Market - Live News